Comparing a new treatment for advanced head and neck cancer that has stopped responding to standard care
Treatments studied
Part of Cancer clinical trials.
This study tests a new drug called MRG003 against two other treatments (cetuximab or methotrexate) for people with a type of head and neck cancer that has come back or spread and has not responded to standard treatments. The goal is to see if the new drug can better control the cancer and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a confirmed diagnosis of squamous cell carcinoma of the head and neck (in the mouth, throat, voice box, or lower throat) that has come back or spread.
- You have already tried two or fewer lines of treatment, including a PD-1/PD-L1 inhibitor (like pembrolizumab or nivolumab) and a platinum-based chemotherapy (like cisplatin).
- You have at least one measurable tumor that can be seen on scans or exams.
- You are physically able to perform daily activities (ECOG score 0 or 1).
- Your blood counts, liver, kidney, and heart function are within acceptable levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two medications—cetuximab (a targeted antibody) and either pembrolizumab or finotonlimab (immunotherapies)—along with chemotherapy, for advanced head and neck cancer that has spread or come back. The goal is to see if this combination helps shrink tumors and improve survival compared to standard treatment.
This trial tests a new drug called SIBP-03 for people with head and neck squamous cell carcinoma that has come back or spread. It is for those whose cancer has worsened after prior immunotherapy and platinum chemotherapy, and who have no option for curative local treatment.
This trial tests two new drugs, BL-B01D1 and SI-B003, alone or together, for people with head and neck squamous cell carcinoma that has come back or spread. It may also include other solid tumors. The goal is to see if these drugs can shrink tumors or slow their growth.
This trial tests a new drug called becotatug vedotin (MRG003) for patients with advanced liver cancer that has progressed despite previous immunotherapy. The drug is designed to target cancer cells while potentially causing less harm to healthy tissue.
This study tests a new combination treatment for head and neck cancer that has come back or spread and has a specific genetic change (CDKN2A mutation). The treatment combines an antibody-drug conjugate (a targeted therapy) with a CDK4/6 inhibitor (a drug that helps stop cancer cells from dividing). It may help people who have already tried standard treatments like immunotherapy or chemotherapy.
This trial tests a drug called MRG003 for people with certain advanced cancers that have a specific protein, EGFR. The drug targets the cancer cells that have this protein, which may help stop the cancer from growing.
Hear when a new Squamous Cell Carcinoma of the Head and Neck trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.